FDA Approves DIPENTUM — Viatris Specialty LLC

Viatris Specialty LLC has received FDA approval for DIPENTUM (olsalazine sodium) Oral Suspension, an updated formulation of the drug originally approved in 1990 to assist in the relief of mild to moderate ulcerative colitis and maintain remission. This regulatory clearance is expected to bolster the manufacturer's commercial portfolio amid continuing demand for colorectal disorder therapies by ensuring a stable supply of this versatile oral suspension.